- Home
- IDYA vs SBLK Comparison
IDYA vs SBLK Comparison
Compare IDYA & SBLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- SBLK
- Stock Information
- Founded
- IDYA 2015
- SBLK 2006
- Country
- IDYA United States
- SBLK Greece
- Employees
- IDYA N/A
- SBLK N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- SBLK Marine Transportation
- Sector
- IDYA Health Care
- SBLK Consumer Discretionary
- Exchange
- IDYA Nasdaq
- SBLK Nasdaq
- Market Cap
- IDYA 2.3B
- SBLK 2.1B
- IPO Year
- IDYA 2019
- SBLK N/A
- Fundamental
- Price
- IDYA $32.18
- SBLK $18.57
- Analyst Decision
- IDYA Buy
- SBLK Buy
- Analyst Count
- IDYA 17
- SBLK 2
- Target Price
- IDYA $48.20
- SBLK $21.50
- AVG Volume (30 Days)
- IDYA 1.3M
- SBLK 862.9K
- Earning Date
- IDYA 11-04-2025
- SBLK 11-18-2025
- Dividend Yield
- IDYA N/A
- SBLK 1.08%
- EPS Growth
- IDYA N/A
- SBLK N/A
- EPS
- IDYA N/A
- SBLK 1.05
- Revenue
- IDYA $7,000,000.00
- SBLK $1,131,251,000.00
- Revenue This Year
- IDYA $90.17
- SBLK N/A
- Revenue Next Year
- IDYA $219.42
- SBLK $19.06
- P/E Ratio
- IDYA N/A
- SBLK $17.64
- Revenue Growth
- IDYA N/A
- SBLK 2.95
- 52 Week Low
- IDYA $13.45
- SBLK $12.06
- 52 Week High
- IDYA $33.64
- SBLK $20.54
- Technical
- Relative Strength Index (RSI)
- IDYA 67.18
- SBLK 57.18
- Support Level
- IDYA $28.17
- SBLK $17.47
- Resistance Level
- IDYA $33.64
- SBLK $17.98
- Average True Range (ATR)
- IDYA 1.68
- SBLK 0.45
- MACD
- IDYA 0.40
- SBLK 0.13
- Stochastic Oscillator
- IDYA 80.76
- SBLK 88.52
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About SBLK Star Bulk Carriers Corp.
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. It generates revenues through the voyages it carries out.